Janssen And Sanofi Keep Mum On EU Fast-Track Request Outcomes

Have Teclistamab And Nirsevimab Made The Grade For Speedy Review At The EMA?

 
• By Maureen Kenny
  
Timer
Shorter review timelines are available for innovative new therapies • Source: Shutterstock: Africa Studio
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

More from Geography